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Objective: To investigate the incidence of serious adverse events (SAE) of subthalamic
deep brain stimulation (STN-DBS) in elderly patients with Parkinson’s disease (PD).
Methods: We investigated a group of 26 patients with PD who underwent STN-DBS
at mean age 63.2 ± 3.3 years. The operated patients from the EARLYSTIM study (mean
age 52.9 ± 6.6) were used as a comparison group. Incidences of SAE were compared
between these groups.
Results: A higher incidence of psychosis and hallucinations was found in these elderly
patients compared to the younger patients in the EARLYSTIM study (p < 0.01).
Conclusions: The higher incidence of STN-DBS-related psychiatric complications
underscores the need for comprehensive psychiatric pre- and postoperative assessment
in older DBS candidates. However, these psychiatric SAEwere transient, and the benefits
of DBS clearly outweighed its adverse effects.
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INTRODUCTION
Deep brain stimulation (DBS) is widely used as a neurosurgical treatment for Parkinson’s
disease (PD), because it improves the motor manifestations of PD and reduces the need for
antiparkinsonianmedication (Fasano and Lozano, 2015). The intraoperative, short-term, and long-
term adverse effects of DBS in PD are well-known (Falowski et al., 2015). However, when candidates
for DBS are appropriately selected, the benefit of the procedure in terms of an improved quality
of life generally justifies its small risk. Moreover, it was concluded in the EARLYSTIM study
(Schuepbach et al., 2013) that DBS in the subthalamic nucleus (STN-DBS) yielded a better outcome
than drug treatment alone in patients with early (rather than advanced)motor complications of PD.
In that study, the incidence of serious adverse events (SAE) was compared in patients in themedical
versus the surgical arms of the study. The mean age of the 124 patients who underwent surgery was
52.9 years, and they were followed up for 2 years. Today, no consensus exists regarding an age cut-
off for DBS as a treatment of PD (Vesper et al., 2007; Floden et al., 2014). In the present study, we
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retrospectively determined the incidence of SAE after STN-DBS
in a group of patients whose mean age was 63.2 years and
compared it to the incidence of SAE among the patients in the
EARLYSTIM study.
METHODS
Patients
We retrospectively analyzed the medical records of PD patients
who underwent STN-DBS in our institution, which were
extracted from the clinical and research databases of the
University Hospital Basel. The study protocol was approved by
the local ethics committee (Ethikkommission beider Basel). The
records were analyzed for a period of 2 years after STN-DBS.
The inclusion and exclusion criteria from the EARLYSTIM study
(Schuepbach et al., 2013) were used to select cases for the analysis,
with the exception of age: in the present study we focused on a
group of relatively old operated patients (see Supplement 1 for the
criteria of selection). The age of the patients in the EARLYSTIM
study ranged from 18 to 60 years; in the group of patients from
our database, the age ranged from 58 to 70 years.
Twenty-six patients with PD (11 women, 15 men) who
underwent STN-DBS from January 1, 2008 to June 30, 2013, were
selected for the analysis (i.e., the “BASEL group” of patients in
what follows, as opposed to the “EARLYSTIM group”).
Operative Procedure for STN-DBS
In each patient, Medtronic 3389 electrodes were stereotactically
implanted into the STN bilaterally under local anesthesia with
the aid of intraoperative microelectrode recording and test
stimulation, after coordinate- and visually-based target selection
and trajectory calculation with the aid of preoperative CT and
MRI scans. The pulse generator was implanted subsequently
under general anesthesia.
Analyses of the Cases
Patients with PD who were scheduled for DBS underwent
interdisciplinary assessment (including detailed neurological and
neuropsychological examinations) before and, in general, every
6 months after the procedure. The results of these assessments
were stored in the hospital’s clinical and research databases and
were compiled for this analysis. Whenever a patient needed
his/her family doctor’s assistance for problems potentially related
to Parkinson’s disease or to DBS, but was not admitted to the
hospital for these problems, the family doctor reported such
cases to the clinical and research database. The interdisciplinary
assessment performed within the 14 days before the STN-DBS
will be referred to as the “baseline assessment,” while that
performed 24 months later will be referred to as the “2-year
assessment.”
The following variables were analyzed: subscales II and III of
the Unified Parkinson’s Disease Rating Scale (UPDRS), the Brief
Psychiatric Rating Scale (BPRS), the Beck Depression Inventory
II (BDI II), and the levodopa equivalent daily dose (LEDD). In
some cases, diagnoses made by other medical specialists (e.g.,
a cardiologist) were used in addition as an indication of the
patient’s general medical condition.
SAE were defined according to the Medical Dictionary for
Regulatory Activities, version 14.1, as any registered events that
led to death, disability, or prolonged or new hospitalization
with serious health impairment. The list of SAE was adjusted
to the list of SAE described in the EARLYSTIM study. Thus,
the SAE were grouped in the following categories: (1) suicide,
(2) life-threatening events, (3) events related to medication or
stimulation, (4) events related to surgery or device, (5) events
related to PD. We calculated the number of reported SAE in each
category for each patient within the 24 months after STN-DBS.
Statistical Analysis
Statistical calculations were done with the R version 3.1.2 open
source software. Baseline mean and standard deviations of
the demographic and clinical parameters of the groups were
compared with an unpaired Student’s t-test. The numbers of
patients with SAE were compared with the chi-squared test
with Yates correction to prevent overestimation of statistical
significance for small data; significance was set at p < 0.05.
Linear regression models were applied to adjust for potential
confounders in statistically significant differences.
RESULTS
The results of the comparison of the demographic and clinical
features of the two groups are shown in Supplement 2. The
patients in the BASEL group were older than the patients in
the EARLYSTIM study who underwent surgery (mean difference
10.3 years, 95% confidence interval (CI) 7.7 to 12.9). Disease
duration in the BASEL group was longer (mean difference 2.7
years, CI: 1.3 to 4.1).
The results of the comparison of SAE incidence between the
two groups are shown in Table 1. Significant differences in the
incidence of SAE were found in the category “Event related
to medication or stimulation” (Chi-squared = 4.5, p = 0.03)
and in its subcategory “psychosis and hallucinations” (Chi-
squared = 24.7, p < 0.01). The characteristics of psychosis and
hallucination of the patients in the BASEL group are shown in
Table 2. Regression models showed no influence of clinical and
demographic parameters on the incidence of psychosis.
DISCUSSION
We found a higher incidence of psychosis and hallucinations after
STN-DBS in a sample of PD patients who were about 10 years
older than those of the EARLYSTIM study.
The effects of DBS on mental functioning are not clear,
and the pattern and expression of neuropsychiatric symptoms
in operated patients with PD are highly variable (Volkmann
et al., 2010). Some researchers have reported various types
of psychiatric side effects of DBS, ranging from apathy and
emotional lability to visual hallucinations, hypersexuality, and
aggressive behavior (Soulas et al., 2008; Le Jeune et al., 2009;
Bickel et al., 2010; Daniele et al., 2012; Qureshi et al., 2015). In a
meta-analysis of 808 publications covering the years 1996–2005,
the most common psychiatric side effect associated with DBS
was delirium, making up 4 to 8% of all psychiatric complications
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TABLE 1 | Serious adverse events in the first 2 years after STN-DBS surgery.
Parameters EARLYSTIM STN-DBS (n = 124) BASEL group (n = 26) Chi-square test, p-value
Event No. of events No. of patients (%) No. of events No. of patients (%)
Total serious adverse events 123 68 (54.8) 61 18 (69.2) ns
1. Death, all by suicide 2 2 (1.6) 0 0 ns
2. Life-threatening event 14 12 (9.7) 2 2 (7.7) ns
3. Event related to medication or stimulation 24 24 (19.4) 10 10 (38.5) 0.03
Worsening of mobility* 5 5 (4.0) 1 1 (3.8) ns
Motor fluctuations 0 0 1 1 (3.8) ns
Dyskinesia 1 1 (0.8) 0 0 ns
Psychosis or hallucinations 0 0 5 5 (19.2) <0.01
Anxiety 0 0 0 0 –
Impulse control disorder 1 1 (0.8) 0 0 ns
Depression 6 6 (4.8) 2 2 (7.7) ns
Suicidal ideation 1 1 (0.8) 0 0 ns
Suicidal attempt 2 2 (1.6) 0 0 ns
Cardiac disorder 0 0 0 0 –
Injury 3 3 (2.4) 0 0 ns
Respiratory or thoracic disorder 1 1 (0.8) 0 0 ns
Other 4 4 (3.2) 0 0 ns
4. Event related to surgery or device 26 22 (17.7) 8 8 (30.8) ns
Impaired wound healing 4 4 (3.2) 2 2 (7.7) ns
Intracerebral abscess or edema 2 2 (1.6) 2 2 (7.7) ns
Dislocation of device** 5 4 (3.2) 1 1 (3.8) ns
Reoperation necessary*** 4 2 (1.6) 2 2 (7.7) ns
Other 11 10 (8.1) 1 1 (3.8) ns
5. Event related to PD 57 39 (31.5) 41 10 (38.5) ns
*Worsening of mobility was defined as tremor, rigidity, akinesia, wearing off of medication effect, dystonia, or worsening of symptoms of PD. **Dislocation of device was defined as
dislocation of the stimulator, cable, or lead. ***Reoperation was necessary in order to repair the stimulator or lead.
TABLE 2 | Patients with serious psychosis and hallucinations.
No Age (years) Sex Clinical presentation Time of manifest after STN-DBS Result
1 60 Female Visual illusions, sense of presence, fear 8 weeks New hospitalization
2 62 Female Delusion of spousal infidelity, suspicions of harmful thoughts 8 weeks New hospitalization
3 60 Male Passage hallucinations, delusion 16 weeks New hospitalization
4 69 Male Paranoia with aggression 10 days Prolonged hospitalization
5 63 Female Visual illusions, sense of presence, fear 12 weeks New hospitalization
(Appleby et al., 2007). The psychiatric side effects of DBS are
usually transient and treatable (Voon et al., 2006), but there
have been case reports of very severe side effects with long-term
consequences (Zonana et al., 2011; Piccoli et al., 2015). Other
researchers reported an improvement of psychiatric symptoms
after DBS (Funkiewiez et al., 2004). Vesper et al. analyzed the
outcomes of DBS in PD as a function of age (Vesper et al., 2007),
comparing patients over and under age 65 1 year after surgery.
Transient neuropsychiatric impairment was a common finding in
both groups (the adverse events were not stratified with regard to
severity). In another observational study by Shiina et al. a sample
of PD patients with a mean age of 65 years was followed up for
12 months after DBS (Shiina et al., 2015): some experienced an
improvement of pre-operative psychiatric symptoms, some had
psychiatric side effects, and others had no changes in psychiatric
state. Piasecki et al. proposed three possible mechanisms of
mental disturbance after DBS: effects of the electrode placement
itself, neurotransmitter changes induced by stimulation, and
worsening of a pre-existingmental disorder by DBS (Piasecki and
Jefferson, 2004). Three regions have been described in the STN in
which the neurons participate in the following functional circuits:
sensorimotor (dorsolateral), motor (ventromedial), and limbic
(medial) (Romanelli et al., 2004). Limbic circuits play a role in
emotional and behavioral control. Spread of electrical current
from the subthalamic DBS electrodes may cause a disturbance
in the limbic circuit, producing psychiatric symptoms. Another
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explanatory hypothesis for psychiatric complications after DBS is
based on an imbalance of two neuromodulators, γ-aminobutyric
acid (GABA), and glutamate. DBS leads to an increased activity
of nigral GABAergic neurons and decreased activity of glutamate
flow from the STN (Malhi and Sachdev, 2002; Piasecki and
Jefferson, 2004). Dysfunction of these transmitters is known
to be involved in psychiatric disorders (Drevets et al., 1997).
Another possible explanation of post-DBS psychosis is the
reduction or withdrawal of dopaminergic medication after
surgery (Voon et al., 2006). Finally, some researchers have
seen a relation between post-DBS psychosis and pre-existing
mental disturbances and have therefore stressed the importance
of a thorough psychiatric assessment as a prerequisite for DBS
surgery (Kalteis et al., 2006). We hypothesize that the psychiatric
SAE in our study were of multifactorial origin and that their
higher incidence in older patients may be explained by these
patients’ lower resistance to surgical stress and their decreased
neuroplasticity, resulting in a poorer ability to reset the functional
limbic circuit affected by PD and DBS (Saint-Cyr et al., 2000).
It should be noted that the STN is not the only possible
target for DBS in the treatment of PD. In particular, DBS in the
internal segment of the globus pallidus (GPi) has been found
to be comparable to STN-DBS in terms of efficacy and safety
(Honey et al., 2016). However, GPi-DBS has its own benefits and
limitations (Groiss et al., 2009). Some centers favor the pallidal
target for certain groups of patients (Okun et al., 2009).
Our analysis has several limitations. First, the patients from
the BASEL group were not very old, but still within the
generally accepted age limits for the operation (Okun and Foote,
2010). Second, while the EARLYSTIM data were obtained in a
multicenter trial, the findings we report here are derived from
a single center. Single-center analyses have a role in planning
and powering of subsequent larger studies (Bellomo et al., 2009);
thus, this report may serve as a starting point for further research
into the age-dependent effects of DBS in PD. Finally, a detailed
comparison of the cognitive performance of the patients in the
two groups is impossible on the basis of the information available
in the EARLYSTIM report.
In spite of these limitations, a comparison of these two
groups enabled us to estimate the influence of age on the
neuropsychiatric and neuropsychological outcome of STN-DBS
surgery in patients with PD. The apparently higher incidence
of psychiatric complications after STN-DBS in older patients
underscores the need for comprehensive pre- and postoperative
psychiatric assessment in older DBS patients. However, the
psychiatric SAE that arose in our patients (the BASEL group)
were transient, occurring mainly in the early postoperative
period. The benefits of DBS clearly outweighed its adverse effects
in this group of patients.
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